Pfizer Licenses eFFECTOR's eIF4E Inhibitors to Bolster Oncology Pipeline

By Neha Madhwani

Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)

Published: 29 Jan-2020

DOI: 10.3833/pdr.v2020.i1.2507     ISSN: 1756-7874

Section: Licensing



Pfizer has entered into a licensing agreement with eFFECTOR Therapeutics to develop and commercialise translation regulation therapies for the treatment of cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details